Stocks Health care BRVE
NASDAQ · Health careBraveheart Bio, Inc. (BRVE)
At June 30, 2026 it held $122.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 8, 2026.
What Braveheart Bio, Inc. does
Braveheart Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BRVE.
Latest SEC filings
What Braveheart Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026Activist stake changed SCHEDULE 13D/A
- September 8, 2026Quarterly report 10-Q · period to June 30, 2026
- September 8, 2026
- August 18, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026
- August 6, 2026
- August 6, 2026
- August 5, 2026Form S-1MEF filing S-1MEF
Insider trades
What the people running Braveheart Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about BRVE
What does Braveheart Bio, Inc. do?
Braveheart Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BRVE.
When did Braveheart Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 8, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from September 10, 2026.
Similar companies
Compare BRVE with
Follow BRVE
Get an email when Braveheart Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BRVE: get an email when it filesWhere the numbers come from
Financial figures are the values Braveheart Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.